Bristol-Myers Squibb R&D is a science-driven, passionate organization determined to discover, develop and deliver medicines that have the potential to transform the lives of patients and establish new standards of care in areas of high un-met need. Patients’ needs and scientific discovery are our driving force. The new Bristol-Myers Squibb research site in Cambridge’s Kendall Square will position our scientific team in the heart of a vibrant ecosystem of world-class science, innovation and business opportunities. Our scientists will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies. These are significant challenges that will require innovative solutions from the biopharma, biotech and academic communities.
Role / Responsibilities
We are seeking an experienced research pathologist to join our Cambridge Translational Pathology group in our new state-of-the-art facility. The qualified candidate is a highly motivated, interactive, and creative individual that possesses the ability to work across a highly matrixed environment to advance the translational medicine efforts. The candidate will be expected to lead a team of histopathology researchers, liaise closely with the Translational Research team to provide pathology and assay development support, as well as forge strong links across the wider translational medicine, discovery and clinical teams.
This position requires an MD, or their foreign equivalents, with Board Certification in Anatomic Pathology, or combined Anatomic Pathology/Laboratory Medicine. A Ph.D. degree in a related field and/or pathology subspecialty certification, in addition to the MD degree, will be highly desirable and a clear demonstration of high quality scholarly productivity in a relevant field of biomedical research is required. We seek candidates with excellent traditional diagnostic pathology skills who demonstrate a strong ability to interpret pathology data in the context of a detailed and current understanding of molecular and cellular biology concepts. Candidates must have demonstrated their ability to handle several projects at any given time, to work successfully and collaboratively in teams and to communicate clearly both verbally and in writing to a variety of audiences.
- MD/PhD or MD with completion of anatomic pathology and/or clinical pathology residency required. Completion of molecular pathology fellowship is desirable but not essential.
- Experienced pathologist in a translational setting with 2-5+ years’ of post-graduate research experience.
- Recent experience in leading scientific teams in an academic or industry setting would be advantageous.
- Participated in clinical studies to better characterize the cellular and molecular underpinnings of therapeutic resistance in patient cohorts and correlation with clinical outcome.
- Strong skill set in developing and implementing multiplexed immunohistochemistry methodologies from antibody selection, staining optimization, pre-analytical variables assessment to downstream digital and imaging strategies with data dissemination and evaluation capabilities.
- Image analysis experience is desired but not a requirement.
- Exposure to cancer immunotherapy including immune-checkpoint blockade with knowledge of current therapeutic landscape is highly desirable.
- Prior role in multidisciplinary projects and teams with ability to integrate cross-functional information, desired but not required.
- Experience with managing CRO relationships and collaborating with KOL’s would be advantageous.
- Excellent interpersonal skills and ability to communicate, both written and oral effectively and efficiently within the BMS organization and with external partners/collaborators.
- Thrives in fast-paced, dynamic work environment, bringing a pro-active mentality to the role.
We follow the science and we will continue to invest in translational medicine research, deepen our understanding of disease biology and uncover insights about predictive biomarkers with the ultimate goal of making precision medicine a reality for more patients.